Elisabeth I Minder

Summary

Publications

  1. pmc Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal
    Elisabeth I Minder
    Stadtspital Triemli, Zentrallabor, Birmensdorferstrasse 497, CH 8063 Zurich, Switzerland
    Health Qual Life Outcomes 8:60. 2010
  2. pmc Effects of different centrifugation conditions on clinical chemistry and Immunology test results
    Elisabeth I Minder
    Stadtspital Triemli, Central laboratory Birmensdorferstrasse 497 CH 8063 Zürich Switzerland
    BMC Clin Pathol 11:6. 2011
  3. doi request reprint Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone
    Juergen H Harms
    Stadtspital Triemli, Central Laboratory, University Hospital of Zurich, Zurich, Switzerland
    Photochem Photobiol 85:1434-9. 2009
  4. doi request reprint Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias
    Xiaoye Schneider-Yin
    Institute of Laboratory Medicine and Swiss Porphyrin Reference Laboratory, Stadtspital Triemli, Zurich, Switzerland
    J Hepatol 62:734-8. 2015
  5. doi request reprint Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria
    Elisabeth I Minder
    Institute of Laboratory Medicine, Stadtspital Triemli, CH 8063 Zurich, Switzerland
    Expert Rev Clin Pharmacol 8:43-53. 2015
  6. doi request reprint Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF(65.)
    Jasmin Barman-Aksözen
    Institute of Laboratory Medicine, Stadtspital Triemli, Zurich, Switzerland
    Blood Cells Mol Dis 51:151-61. 2013

Collaborators

  • Peter Bauer
  • Xiaoye Schneider-Yin
  • Jasmin Barman-Aksözen
  • Juergen H Harms
  • Paul Komminoth
  • Roy H E Cloots
  • Ann Driessen
  • Reno S Bladergroen
  • Axel zur Hausen
  • Jorge Frank
  • Markus Weber
  • Philip Went
  • Michel van Geel
  • Marko Siegesmund
  • Pamela Poblete-Gutiérrez
  • Anne Moon van Tuyll van Serooskerken
  • CHRISTOPHER SCHROEDER
  • Véronique J Winnepenninckx
  • Afzal M Dogar
  • Chantal Béguin
  • Stephan Lautenschlager
  • Christoph E Minder

Detail Information

Publications6

  1. pmc Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal
    Elisabeth I Minder
    Stadtspital Triemli, Zentrallabor, Birmensdorferstrasse 497, CH 8063 Zurich, Switzerland
    Health Qual Life Outcomes 8:60. 2010
    ..No standardized tools to quantify the degree of PP-related phototoxicity and its change by medical intervention have been published...
  2. pmc Effects of different centrifugation conditions on clinical chemistry and Immunology test results
    Elisabeth I Minder
    Stadtspital Triemli, Central laboratory Birmensdorferstrasse 497 CH 8063 Zürich Switzerland
    BMC Clin Pathol 11:6. 2011
    ..abstract:..
  3. doi request reprint Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone
    Juergen H Harms
    Stadtspital Triemli, Central Laboratory, University Hospital of Zurich, Zurich, Switzerland
    Photochem Photobiol 85:1434-9. 2009
    ..The findings demonstrate beneficial effects of afamelanotide in patients with EPP. Due to the limited number of patients enrolled and the design being an open-label study, confirmation by a large-scale trial is required...
  4. doi request reprint Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias
    Xiaoye Schneider-Yin
    Institute of Laboratory Medicine and Swiss Porphyrin Reference Laboratory, Stadtspital Triemli, Zurich, Switzerland
    J Hepatol 62:734-8. 2015
    ..Both PPOX and HMBS, which might act as tumor suppressors, play a crucial role in the development of HCC in these individuals. ..
  5. doi request reprint Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria
    Elisabeth I Minder
    Institute of Laboratory Medicine, Stadtspital Triemli, CH 8063 Zurich, Switzerland
    Expert Rev Clin Pharmacol 8:43-53. 2015
    ..Moreover, we hope that dosage forms suitable for children will be developed in future, as children and adolescents suffer most in protoporphyria. ..
  6. doi request reprint Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF(65.)
    Jasmin Barman-Aksözen
    Institute of Laboratory Medicine, Stadtspital Triemli, Zurich, Switzerland
    Blood Cells Mol Dis 51:151-61. 2013
    ..This in turn, influences the relative amounts of correct and aberrant FECH mRNA splice products and thus, regulates the FECH enzyme activity. ..